Wealth Enhancement Advisory Services
GANX icon

Wealth Enhancement Advisory Services’s Gain Therapeutics GANX Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.7K Buy
17,056
+1,500
+10% +$2.77K ﹤0.01% 3992
2026
Q1 		$28.8K Hold
15,556
– – ﹤0.01% 3477
2025
Q4 		$39.7K Hold
15,556
– – ﹤0.01% 3542
2025
Q3 		$31.4K Buy
+15,556
New +$26.2K ﹤0.01% 3471

Other funds holding GANX

BFA
Benedict Financial Advisors Atlanta, Georgia $515M AUM 24.59% 1-Year Est. Return
OLA
Oliver Luxxe Assets Gladstone, New Jersey $680M AUM 47.51% 1-Year Est. Return

Wealth Enhancement Advisory Services's GANX Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its Gain Therapeutics (GANX) stake by 9.6% in Q2 2026, buying an estimated $2.77K and bringing the position to 17,056 shares worth $30.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3992.

Wealth Enhancement Advisory Services first reported a position in GANX in Q3 2025 and has held it in 4 quarters since. The position peaked at $39.7K in Q4 2025. 3 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

  • Wealth Enhancement Advisory Services held 17,056 shares of Gain Therapeutics worth $30.7K as of Q2 2026.
  • Wealth Enhancement Advisory Services bought 1,500 Gain Therapeutics shares in Q2 2026, an estimated $2.77K.
  • Gain Therapeutics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #3992 holding.
  • Wealth Enhancement Advisory Services first reported a position in Gain Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Wealth Enhancement Advisory Services's Gain Therapeutics position peaked at $39.7K in Q4 2025.
  • 3 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.